FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell Lung Cancer By Ogkologos - January 22, 2026 313 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Olaparib Plus Bevacizumab Provides Clinically Meaningful OS Improvement for Newly Diagnosed... May 31, 2023 COVID-19 Vaccination Efficient in Patients with Cancer Who Receive Active Anticancer... August 9, 2021 The Childhood Cancer Data Initiative: Transforming the Pediatric Cancer Landscape through... August 15, 2019 Turning the Life Sciences Vision into reality July 9, 2021 Load more HOT NEWS Axicabtagene Ciloleucel Results in High Response Rates and Durable Remissions as... 確診癌症後患者應如何面對悲傷 Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or... Patient Guide on Immunotherapy Side Effects and Their Management Now Available...
